Recognizing the importance of addressing the evolving needs of the hospital marketplace and growing alternate sites of care, Pfizer established the Hospital Business Unit (HBU) in 2019 to ensure vital medicines are delivered to patients, providers and customers where they are needed most.
As a startup within the Biopharmaceuticals Group, the HBU was quickly formed to be a global business with one of the broadest portfolios of medicine in the industry. As the only customer- and channel-centric business in Pfizer, the HBU addresses the growing needs of hospitals and the patients they serve. It combines a world-leading sterile injectables portfolio and the number one anti-infectives portfolio with our legacy hospital brands, Pfizer CentreOne and Meridian Medical Technologies.
Beyond medicines, Pfizer’s HBU is focused on developing innovative delivery systems and advancing our go-to-market model through pioneering in contracting. The HBU is also leading the way in promotion of global antimicrobial stewardship through innovative surveillance tools, global policy research and education programs.
With an unmatched depth and breadth of portfolio and capabilities rooted in Pfizer’s decades of experience, the HBU is committed to Breakthroughs that change patients’ lives.
.jpg)
Share this page
